Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study

Giuseppe Di Lorenzo, Riccardo Autorino, Sisto Perdonà, Michele De Laurentiis, Massimo D'Armiento, Giuseppe Cancello, Vincenzo Mirone, Ciro Imbimbo, Nicola Longo, Vincenzo Altieri, Gianpaolo Tortora, William D. Figg, Sabino De Placido

Research output: Contribution to journalArticle

Abstract

Objectives: Combining antineoplastic agents is the key to improving the treatment options for men with hormone refractory prostate cancer (HRPC). The current study investigated the combination of docetaxel, vinorelbine, and zoledronic acid as a first-line treatment for HRPC. Methods: Patients were treated repeatedly with docetaxel (25 mg/mq) and vinorelbine (10 mg/mq) intravenously for three consecutive weeks followed by a 1-wk rest until disease progression or side effects. Zoledronic acid was administered every 4 wk. Changes in prostate-specific antigen (PSA) levels and objective responses were evaluated after two and three cycles, respectively. Toxicity and pain evaluation, based on pain intensity reduction and analgesic drug reduction, were assessed every cycle. Results: Forty men with HRPC (median age: 65 yr) were treated. Among 38 evaluable patients, complete and major PSA responses were observed in seven (18%) and 12 (32%), respectively; a partial objective response was observed in six of 15 (40%) patients with measurable disease. Neutropenia (25%) was the most important grade 3 haematologic toxicity observed. Only three patients (7.5%) reported grade 4 neutropenia. Nineteen patients (47.5%) achieved a reduction of pain intensity and analgesic drug use after two cycles. Median progression-free survival was 7 mo (95% CI: 2-10 mo), with a median overall survival of 17 mo (95% CI: 6-22 mo). Conclusions: The combination of docetaxel, vinorelbine, and zoledronic acid is associated with improvement in biochemical, objective, and pain responses and is well tolerated as a first-line treatment for HRPC.

Original languageEnglish
Pages (from-to)1020-1027
Number of pages8
JournalEuropean Urology
Volume52
Issue number4
DOIs
Publication statusPublished - Oct 2007

    Fingerprint

Keywords

  • Chemotherapy
  • Hormone refractory prostate cancer
  • Prostate-specific antigen
  • Toxicity

ASJC Scopus subject areas

  • Urology

Cite this

Di Lorenzo, G., Autorino, R., Perdonà, S., De Laurentiis, M., D'Armiento, M., Cancello, G., Mirone, V., Imbimbo, C., Longo, N., Altieri, V., Tortora, G., Figg, W. D., & De Placido, S. (2007). Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study. European Urology, 52(4), 1020-1027. https://doi.org/10.1016/j.eururo.2007.02.060